Speaker illustration

Professor Wolfgang Koenig

German Heart Center of Munich,, Munich (Germany)

Member of:

European Society of Cardiology

Wolfgang Koenig, MD, FRCP, FACC, FAHA, FESC is a Professor of Cardiology. A former Director of the WHO-MONICA Augsburg Myocardial Infarction Registry, he has held multiple clinical positions at the University of Ulm Medical Center. In April 2015 he joined the Deutsches Herzzentrum München, where he is the Head of the Cardiometabolic Unit. Professor Koenig serves on the steering committee of multiple large clinical trials. His research also includes the molecular basis of atherothrombogenesis, and focuses on the identification and evaluation of new biomarkers for cardiometabolic diseases. He has published more than 900 papers in peer-reviewed journals. Between 2008–2017, he ranked sixtieth among the most frequently cited German speaking researchers in cardiovascular disease and has an H-Index of 101. He is a member of the Editorial Board of “Clinical Chemistry”. In 2020 he received the Paul-Morawitz-Award from the German Cardiac Society.

Prevention of cardiovascular diseases in the post-COVID19 era

Event: ESC Congress 2022

Topic: Prevention

Session type: Satellite Symposium

Thumbnail

Cardiac biomarkers for atherosclerotic cardiovascular disease risk prediction

Event: ESC Congress 2021 - The Digital Experience

Topic: Biomarkers

Session type: Advances in Science

Thumbnail

Emerging role of cardiac biomarkers in cardiovascular risk stratification

Event: ESC Preventive Cardiology 2021

Topic: Biomarkers

Session type: Satellite Symposium

Thumbnail

Non-troponin biomarkers in acute coronary syndromes

Event: ESC CONGRESS 2019

Topic: Biomarkers

Session type: Abstract Sessions

Thumbnail

Emerging evidence-based approaches to reduce residual atherosclerotic risk

Event: ESC Congress 2018

Topic: Risk Factors and Prevention

Session type: Satellite Symposium

Thumbnail

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition & cardiovascular outcomes: review of lipid targets and treatment strategies (EBAC Accredited)

Event: ESC CONGRESS 2017

Topic: Drug therapy

Session type: Satellite Symposium

Thumbnail

PCSK9i: translating LDL-C lowering into plaque regression and CV event reduction?

Event: ESC CONGRESS 2016

Topic: Atherosclerosis

Session type: Satellite Symposium - Experts on the Spot

Thumbnail

The relevance of biomarkers: a never ending story

Event: ESC CONGRESS 2016

Topic: Biomarkers

Session type: Moderated Posters

Thumbnail

PCSK9 inhibition in clinical lipid management: a critical review of evidence and opportunities

Event: ESC CONGRESS 2016

Topic: Lipids

Session type: EBAC Accredited Educational Programme

Thumbnail

This platform is supported by

logo Novo Nordisk